[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Obesity (Metabolic Disorder) - Drugs in Development, 2021

October 2021 | 763 pages | ID: OCCB4A7BD3BFEN
Global Markets Direct

US$ 2,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Obesity (Metabolic Disorder) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Obesity - Drugs In Development, 2021, provides an overview of the Obesity (Metabolic Disorders) pipeline landscape.Obesity is defined as having an excessive amount of body fat. Obesity increases risk of diseases and health problems such as heart disease, diabetes and high blood pressure. The predisposing factors include age, family history, quitting smoking, lack of sleep and certain medications. Treatment includes healthy lifestyle, medications and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Obesity - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 7, 30, 37, 1, 4, 145, 59 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 53 and 13 molecules, respectively.

Obesity (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Obesity (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Obesity (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Obesity (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Obesity (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Obesity (Metabolic Disorders)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Obesity (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Obesity (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Obesity - Overview
Obesity - Therapeutics Development
Obesity - Therapeutics Assessment
Obesity - Companies Involved in Therapeutics Development
Obesity - Drug Profiles
Obesity - Dormant Projects
Obesity - Discontinued Products
Obesity - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Obesity, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Obesity - Pipeline by 9 Meters Biopharma Inc, 2021
Obesity - Pipeline by Aardvark Therapeutics Inc, 2021
Obesity - Pipeline by Adare Pharma Solutions, 2021
Obesity - Pipeline by Adipo Therapeutics LLC, 2021
Obesity - Pipeline by Adocia SAS, 2021
Obesity - Pipeline by Agentix Corp, 2021
Obesity - Pipeline by AgeX Therapeutics Inc, 2021
Obesity - Pipeline by Alla Chem LLC, 2021
Obesity - Pipeline by Altimmune Inc, 2021
Obesity - Pipeline by Amgen Inc, 2021
Obesity - Pipeline by Anagenesis Biotechnologies SAS, 2021
Obesity - Pipeline by Antag Therapeutics ApS, 2021
Obesity - Pipeline by AntiCancer Inc, 2021
Obesity - Pipeline by Aoxing Pharmaceutical Company Inc, 2021
Obesity - Pipeline by Applied Molecular Transport Inc, 2021
Obesity - Pipeline by AptamiR Therapeutics Inc, 2021
Obesity - Pipeline by Aptorum Group Ltd, 2021
Obesity - Pipeline by AstraZeneca Plc, 2021
Obesity - Pipeline by August Therapeutics Inc, 2021
Obesity - Pipeline by Auris Medical Holding Ltd, 2021
Obesity - Pipeline by Autotac Bio Inc, 2021
Obesity - Pipeline by Betagenon AB, 2021
Obesity - Pipeline by BioRestorative Therapies Inc, 2021
Obesity - Pipeline by Biozeus Pharmaceutical SA, 2021
Obesity - Pipeline by Boehringer Ingelheim International GmbH, 2021
Obesity - Pipeline by Braasch Biotech LLC, 2021
Obesity - Pipeline by Bristol-Myers Squibb Co, 2021
Obesity - Pipeline by Bukwang Pharmaceutical Co Ltd, 2021
Obesity - Pipeline by Caliway Biopharmaceutics Co Ltd, 2021
Obesity - Pipeline by Callitas Therapeutics Inc, 2021
Obesity - Pipeline by Can-Fite BioPharma Ltd, 2021
Obesity - Pipeline by Carmot Therapeutics Inc, 2021
Obesity - Pipeline by Cellivery Therapeutics Inc, 2021
Obesity - Pipeline by Centeer BioTherapeutics Ltd Co, 2021
Obesity - Pipeline by CinFina Pharma LLC, 2021
Obesity - Pipeline by Circadian Therapeutics, 2021
Obesity - Pipeline by CK Biotech Inc, 2021
Obesity - Pipeline by Clayton Biotechnologies Inc, 2021
Obesity - Pipeline by CohBar Inc, 2021
Obesity - Pipeline by Corbus Pharmaceuticals Inc, 2021
Obesity - Pipeline by Corcept Therapeutics Inc, 2021
Obesity - Pipeline by Courage Therapeutics Inc, 2021
Obesity - Pipeline by CURx Pharmaceuticals Inc, 2021
Obesity - Pipeline by CVI Pharmaceuticals US Inc, 2021
Obesity - Pipeline by Cyrus Therapeutics Inc, 2021
Obesity - Pipeline by D&D Pharmatech Co Ltd, 2021
Obesity - Pipeline by Daewoong Pharmaceutical Co Ltd, 2021
Obesity - Pipeline by DD Therapeutics LLC, 2021
Obesity - Pipeline by Diasome Pharmaceuticals Inc, 2021
Obesity - Pipeline by DiscoveryBiomed Inc, 2021
Obesity - Pipeline by Dompe Farmaceutici SpA, 2021
Obesity - Pipeline by Eccogene (Shanghai) Co Ltd, 2021
Obesity - Pipeline by Elevian Inc, 2021
Obesity - Pipeline by Eli Lilly and Co, 2021
Obesity - Pipeline by Empros Pharma AB, 2021
Obesity - Pipeline by EncuraGen Inc, 2021
Obesity - Pipeline by Energesis Pharmaceuticals Inc, 2021
Obesity - Pipeline by Enspire Bio Inc, 2021
Obesity - Pipeline by Enterin Inc, 2021
Obesity - Pipeline by Eolo Pharma, 2021
Obesity - Pipeline by EraCal Therapeutics AG, 2021
Obesity - Pipeline by ERX Pharmaceuticals Inc, 2021
Obesity - Pipeline by Eternygen GmbH, 2021
Obesity - Pipeline by FGH BioTech Inc, 2021
Obesity - Pipeline by Fzata Inc, 2021
Obesity - Pipeline by Gan & Lee Pharmaceuticals Co Ltd, 2021
Obesity - Pipeline by Gila Therapeutics Inc, 2021
Obesity - Pipeline by Glaceum Inc, 2021
Obesity - Pipeline by Glucox Biotech AB, 2021
Obesity - Pipeline by Gmax Biopharm LLC, 2021
Obesity - Pipeline by GPER G-1 Development Group LLC, 2021
Obesity - Pipeline by Guangzhou BeBetter Medicine Technology Co Ltd, 2021
Obesity - Pipeline by Gubra ApS, 2021
Obesity - Pipeline by Gusto Global LLC, 2021
Obesity - Pipeline by HanAll Biopharma Co Ltd, 2021
Obesity - Pipeline by Hangzhou Adamerck Pharmlabs Inc, 2021
Obesity - Pipeline by Hangzhou Jiuyuan Gene Engineering Co Ltd, 2021
Obesity - Pipeline by Hanmi Pharmaceuticals Co Ltd, 2021
Obesity - Pipeline by HEC Pharma Co Ltd, 2021
Obesity - Pipeline by Huadong Medicine Co Ltd, 2021
Obesity - Pipeline by Ildong Pharmaceutical Co Ltd, 2021
Obesity - Pipeline by Immungenetics AG, 2021
Obesity - Pipeline by ImmunoBiome Inc, 2021
Obesity - Pipeline by Infusion Biosciences, 2021
Obesity - Pipeline by Innovimmune Biotherapeutics Inc, 2021
Obesity - Pipeline by Intarcia Therapeutics Inc, 2021
Obesity - Pipeline by Japan Tobacco Inc, 2021
Obesity - Pipeline by Jenrin Discovery Inc, 2021
Obesity - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, 2021
Obesity - Pipeline by Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd, 2021
Obesity - Pipeline by Johnson & Johnson, 2021
Obesity - Pipeline by Kallyope Inc, 2021
Obesity - Pipeline by KinDex Pharmaceuticals Inc, 2021
Obesity - Pipeline by Kissei Pharmaceutical Co Ltd, 2021
Obesity - Pipeline by Kriya Therapeutics Inc, 2021
Obesity - Pipeline by Kwang Dong Pharmaceutical Co Ltd, 2021
Obesity - Pipeline by Lead Discovery Center GmbH, 2021
Obesity - Pipeline by LG Chem Ltd, 2021
Obesity - Pipeline by Lipidio Pharmaceuticals Inc, 2021
Obesity - Pipeline by Lixte Biotechnology Holdings Inc, 2021
Obesity - Pipeline by MAKScientific LLC, 2021
Obesity - Pipeline by MD Healthcare Inc, 2021
Obesity - Pipeline by MeiraGTx Holdings Plc, 2021
Obesity - Pipeline by Merck & Co Inc, 2021
Obesity - Pipeline by Muen (Guangzhou) Biological Technology Co Ltd, 2021
Obesity - Pipeline by Nano Intelligent Biomedical Engineering Corp, 2021
Obesity - Pipeline by NeonMind Biosciences Inc, 2021
Obesity - Pipeline by NeuroNano Pharma Inc, 2021
Obesity - Pipeline by NGM Biopharmaceuticals Inc, 2021
Obesity - Pipeline by NIMIUM Therapeutics Inc, 2021
Obesity - Pipeline by Nordic Bioscience AS, 2021
Obesity - Pipeline by Novartis AG, 2021
Obesity - Pipeline by NovMetaPharma Co Ltd, 2021
Obesity - Pipeline by Novo Nordisk AS, 2021
Obesity - Pipeline by Nubiyota LLC, 2021
Obesity - Pipeline by NuSirt Biopharma Inc, 2021
Obesity - Pipeline by ObeTherapy Biotechnology, 2021
Obesity - Pipeline by Ochre Bio Ltd, 2021
Obesity - Pipeline by Omeros Corp, 2021
Obesity - Pipeline by Onegene Biotechnology Inc, 2021
Obesity - Pipeline by OPKO Health Inc, 2021
Obesity - Pipeline by Oramed Pharmaceuticals Inc, 2021
Obesity - Pipeline by Orbit Discovery Ltd, 2021
Obesity - Pipeline by Otsuka Holdings Co Ltd, 2021
Obesity - Pipeline by Oxt Therapeutics Inc, 2021
Obesity - Pipeline by Palatin Technologies Inc, 2021
Obesity - Pipeline by PegBio Co Ltd, 2021
Obesity - Pipeline by Pfizer Inc, 2021
Obesity - Pipeline by Preveceutical Medical Inc, 2021
Obesity - Pipeline by Primetime Life Sciences LLC, 2021
Obesity - Pipeline by Pylum Biosciences Inc, 2021
Obesity - Pipeline by Qoracle Co Ltd, 2021
Obesity - Pipeline by Raziel Therapeutics, 2021
Obesity - Pipeline by Regeneron Pharmaceuticals Inc, 2021
Obesity - Pipeline by Renova Therapeutics Inc, 2021
Obesity - Pipeline by Repurpose.AI Inc, 2021
Obesity - Pipeline by Resalis Therapeutics Srl, 2021
Obesity - Pipeline by Reviva Pharmaceuticals Inc, 2021
Obesity - Pipeline by Rhamnopharma Inc, 2021
Obesity - Pipeline by Rhythm Pharmaceuticals Inc, 2021
Obesity - Pipeline by RosVivo Therapeutics Inc, 2021
Obesity - Pipeline by Saniona AB, 2021
Obesity - Pipeline by Sanofi, 2021
Obesity - Pipeline by Scioto Biosciences Inc, 2021
Obesity - Pipeline by Sciwind Biosciences Co Ltd, 2021
Obesity - Pipeline by Scohia Pharma Inc, 2021
Obesity - Pipeline by Senda Biosciences Inc, 2021
Obesity - Pipeline by Seres Therapeutics Inc, 2021
Obesity - Pipeline by Shanghai Fosun Pharmaceutical (Group) Co Ltd, 2021
Obesity - Pipeline by Shionogi & Co Ltd, 2021
Obesity - Pipeline by Sigrid Therapeutics AB, 2021
Obesity - Pipeline by Siragen Pharmaceuticals Inc, 2021
Obesity - Pipeline by SJT Molecular Research SL, 2021
Obesity - Pipeline by SK Plasma Co Ltd, 2021
Obesity - Pipeline by Slate Bio Inc, 2021
Obesity - Pipeline by Soleno Therapeutics Inc, 2021
Obesity - Pipeline by Sun Pharmaceutical Industries Ltd, 2021
Obesity - Pipeline by Takeda Pharmaceutical Co Ltd, 2021
Obesity - Pipeline by Techfields Pharma Co Ltd, 2021
Obesity - Pipeline by Tryp Therapeutics Inc, 2021
Obesity - Pipeline by UGISense AG, 2021
Obesity - Pipeline by Uni-Bio Science Group Ltd, 2021
Obesity - Pipeline by Velabs Therapeutics GmbH, 2021
Obesity - Pipeline by Virtici LLC, 2021
Obesity - Pipeline by Vivus Inc, 2021
Obesity - Pipeline by XL-protein GmbH, 2021
Obesity - Pipeline by YSOPIA Bioscience SA, 2021
Obesity - Pipeline by Yuhan Corp, 2021
Obesity - Pipeline by Zealand Pharma AS, 2021
Obesity - Pipeline by Zhejiang Doer Biologics Corp, 2021
Obesity - Pipeline by Zihipp Ltd, 2021
Obesity - Pipeline by Zylem Biosciences Inc, 2021
Obesity - Dormant Projects, 2021
Obesity - Discontinued Products, 2021

LIST OF FIGURES

Number of Products under Development for Obesity, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021


More Publications